BofA reinstates pharma coverage
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Hungarian Gripen jet crashes, no injuries reported, PM Magyar says
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
Deutsche Bank Reiterates Hold Rating on Gilead Sciences (GILD)
December 11, 2024 6:31 AM ESTDeutsche Bank analyst James Shin reiterated a Hold rating and $73.00 price target on Gilead Sciences (NASDAQ: GILD).
The analyst comments "Big picture - GILD's HIV day demonstrated its HIV franchise has potential to extend into FY2035. GILD is trading at ~12x the Street's 2025E EPS ($7.47/sh), >2- turns... More
Pfizer (PFE) PT Lowered to $28 at Leerink Partners
December 11, 2024 6:24 AM ESTLeerink Partners analyst David Risinger lowered the price target on Pfizer (NYSE: PFE) to $28.00 (from $31.00) while maintaining a Market Perform rating.
The analyst comments "We are lowering our 25E EPS by 10% from $3.12 to $2.82 ahead of the company's 2025 guidance call on Dec 17 at 8:30 am ET; webcast... More
Gilead Sciences (GILD) PT Raised to $99 at Leerink Partners
December 11, 2024 6:21 AM ESTLeerink Partners analyst Andrew Berens raised the price target on Gilead Sciences (NASDAQ: GILD) to $99.00 (from $96.00) while maintaining a Outperform rating.
The analyst comments "Leaving Gileads HIV investors event, we reaffirm our optimism that Gilead can appreciably mitigate the impact of Biktarvys... More
